Vitruvias Therapeutics recalls thyroid tablets over superpotency concerns

Vitruvias Therapeutics Inc. has issued a nationwide recall for one lot of its 30-mg thyroid tablets after testing indicated the tablets could be superpotent. Superpotent tablets pose a risk of hyperthyroidism, which can lead to symptoms such as rapid heart rate, chest pain, and muscle weakness, with patients advised to consult healthcare providers before discontinuing treatment.